Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor | Zendy

Sonya L. Heltshe | Zendy; Nicole Mayer-Hamblett | Zendy; Jane L. Burns | Zendy; Umer Khan | Zendy; Arthur Baines | Zendy; Bonnie W. Ramsey | Zendy; Steven M. Rowe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

Author(s) -

Sonya L. Heltshe,

Nicole Mayer-Hamblett,

Jane L. Burns,

Umer Khan,

Arthur Baines,

Bonnie W. Ramsey,

Steven M. Rowe

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu944

Subject(s) - ivacaftor , cystic fibrosis , medicine , pseudomonas aeruginosa , respiratory system , mutation , cystic fibrosis transmembrane conductance regulator , microbiology and biotechnology , bacteria , gene , genetics , biology

Ivacaftor improves outcomes in cystic fibrosis (CF) patients with the G551D mutation; however, effects on respiratory microbiology are largely unknown. This study examines changes in CF respiratory pathogens with ivacaftor and correlates them with baseline characteristics and clinical response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research